Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107614 · ClinicalTrials.gov registry record · Phase 2
DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients
A Phase 2 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00107614 is a Phase 2 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 12 participants.
The verdict
NCT00107614, a Phase 2 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what the response is and the side effects are with chemotherapy using a combination of drugs called D.T. PACE (Dexamethasone, Thalidomide, cis-Platinum, Adriamycin, Cyclophosphamide, and Etoposide) + Rituxan, followed by two autologous transplants.
Interventions
- DRUG DT PACE + Rituxan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2002-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107614
The ClinicalTrials.gov registry entry for NCT00107614 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DT PACE + Rituxan is the first listed.
NCT00107614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107614 about?
NCT00107614 is a clinical study titled "DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients". The purpose of this study is to find out what the response is and the side effects are with chemotherapy using a combination of drugs called D.T. PACE (Dexamethasone, Thalidomide, cis-Platinum, Adriamycin, Cyclophosphamide, and Etoposide) + Rituxan, followed by two autologous transplants.
What is the current status of trial NCT00107614?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2002-11. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00107614?
The interventions under investigation include: DT PACE + Rituxan (DRUG).
Who is sponsoring clinical trial NCT00107614?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.